CSIMarket
 
Xilio Therapeutics inc   (XLO)
Other Ticker:  
 
 
Price: $0.6850 $0.04 5.939%
Day's High: $0.687 Week Perf: -9.49 %
Day's Low: $ 0.63 30 Day Perf: 14.17 %
Volume (M): 86 52 Wk High: $ 3.67
Volume (M$): $ 59 52 Wk Avg: $2.04
Open: $0.63 52 Wk Low: $0.49



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 28
 Employees 51
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -81
 Cash Flow (TTM) (Millions $) -79
 Capital Exp. (TTM) (Millions $) 1

Xilio Therapeutics Inc
Xilio Therapeutics Inc is a biotechnology company that specializes in the development of tumor-selective immuno-oncology therapies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts, with additional offices in Boston and San Francisco.

Xilio Therapeutics' revolutionary approach is to develop therapies that target cancer cells directly, while sparing normal cells. The company believes that by doing so, they can create more effective therapies that minimize side-effects experienced by patients.

The company's proprietary platform is based on Tumor Selective Immuno-Transfer (TSIT), which is a technology that enables the creation of potent, tumor-selective immunotherapies. TSIT is designed to target multiple mechanisms of immune evasion, which is a major obstacle in the treatment of cancer.

Xilio Therapeutics' lead candidate, XTX202, is a tumor-selective T cell therapy designed to attack solid tumors. XTX202 is being evaluated in preclinical models, and the company anticipates initiating clinical trials in the near future. XTX202 has shown significant efficacy in preclinical models, and the company is hopeful that it will translate into positive clinical results.

The company has also developed a pipeline of additional candidates targeting other types of cancer, including hematologic malignancies and solid tumors. Xilio Therapeutics is led by a team of industry veterans, including CEO Rene Russo and CMO Michel Sadelain, who have a wealth of experience in the development and commercialization of immunotherapies.

Xilio Therapeutics has raised over $100 million in funding to date, including a $95 million Series C financing round in October 2020. The company has partnerships with several leading biotech and pharmaceutical companies, including Boehringer Ingelheim, Roche, and Takeda.

Overall, Xilio Therapeutics Inc represents a promising and innovative approach to developing cancer treatments that could potentially revolutionize the field of immuno-oncology.


   Company Address: 828 Winter Street Waltham 2451 MA
   Company Phone Number: 524-2466   Stock Exchange / Ticker: NASDAQ XLO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Xilio Therapeutics Poised for Breakthrough in Colorectal Cancer Treatment with Promising Phase 1 Results and Initiating Phase 2 Trial

Published Thu, Dec 7 2023 12:30 PM UTC

Xilio Therapeutics Announces Promising Results and Plans for Phase 2 Trial in Colorectal Cancer
Xilio Therapeutics, a leading biotechnology company, recently declared the commencement of patient enrollment for a Phase 1 combination trial of XTX101, its flagship tumor-activated, Fc-enhanced anti-CTLA-4 therapy. Additionally, the company shared updated data from its Phase ...

Xilio Therapeutics Inc

Xilio Therapeutics Inc Shocks the Stock Market with Impressive Financial Gains, Racking Up a $17.361 Million Surplus



In the Major Pharmaceutical Preparations industry, some smaller corporations are beginning to report their financial results. Xilio Therapeutics Inc (Nasdaq: XLO), a clinical-stage biotechnology company, recently announced its operating shortfall for the third quarter of 2023. Despite the deficit, there are some promising aspects to consider. Let's delve into the context of Xilio's financial results and explore the implications for investors.
Q3 2023 Financial Results:
Xilio Therapeutics Inc reported an operating shortfall of $-17.361 million for the third quarter of 2023. While this figure is not ideal, it is a significant improvement from the operating shortfall of $-20.206 million in the same period of the previous year (Q3 2022). This positive trend indicates that the company is actively working towards managing its financials more efficiently.

Xilio Therapeutics Inc

Xilio Therapeutics Inc Reports Operating Loss of $-20.116 Million, Highlighting Positive Momentum in Q2 2023 Results


As an investor tracking the progress of pharmaceutical companies, it always pays off to take a closer look at the overlooked players in the industry. While much of the attention goes to the major pharmaceutical preparations companies, there are some hidden gems that deserve recognition for their efforts. One such corporation is Xilio Therapeutics Inc, which recently released its financial results for the second quarter of 2023.
According to the reports, Xilio Therapeutics Inc revealed an operating loss of $-20.116 million for Q2 2023. However, when compared to the same quarter last year, where the operating loss stood at $-24.552 million, we can clearly see positive signs of improvement. This reduction in operating loss serves as a significant indicator of the course Xilio Therapeutics Inc is heading towards.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com